Novakand Pharma AB (publ) (LARK) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.029x

Based on the latest financial reports, Novakand Pharma AB (publ) (LARK) has a cash flow conversion efficiency ratio of -0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.64 Million ≈ $-176.17K USD) by net assets (Skr55.49 Million ≈ $5.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novakand Pharma AB (publ) balance sheet quality to measure how much of total assets are equity-financed.

Novakand Pharma AB (publ) - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Novakand Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Novakand Pharma AB (publ) cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Novakand Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Novakand Pharma AB (publ) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Dermata Therapeutics Inc NASDAQ:DRMA	-0.214x
TENET FINTECH GROUP INC. F:P0T	-17.433x
Aptevo Therapeutics Inc NASDAQ:APVO	-0.686x
Karma Energy Limited NSE:KARMAENG	0.027x
Pagegroup PLC LSE:PAGE	0.274x
Hapbee Technologies Inc V:HAPB	0.329x
Askari Metals Ltd AU:AS2	-0.195x
Jain Irrigation Systems Limited NSE:JISLDVREQS	0.032x

Annual Cash Flow Conversion Efficiency for Novakand Pharma AB (publ) (2012–2025)

The table below shows the annual cash flow conversion efficiency of Novakand Pharma AB (publ) from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Novakand Pharma AB (publ) worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr55.49 Million ≈ $5.97 Million	Skr-12.78 Million ≈ $-1.38 Million	-0.230x	+44.96%
2024-12-31	Skr71.58 Million ≈ $7.70 Million	Skr-29.95 Million ≈ $-3.22 Million	-0.418x	-59.46%
2023-12-31	Skr116.46 Million ≈ $12.53 Million	Skr-30.56 Million ≈ $-3.29 Million	-0.262x	-139.51%
2022-12-31	Skr152.12 Million ≈ $16.37 Million	Skr-16.67 Million ≈ $-1.79 Million	-0.110x	-178.41%
2021-12-31	Skr158.28 Million ≈ $17.03 Million	Skr22.11 Million ≈ $2.38 Million	0.140x	+126.03%
2020-12-31	Skr71.43 Million ≈ $7.69 Million	Skr-38.35 Million ≈ $-4.13 Million	-0.537x	+49.55%
2019-12-31	Skr20.30 Million ≈ $2.19 Million	Skr-21.60 Million ≈ $-2.33 Million	-1.064x	-9662.78%
2018-12-31	Skr20.46 Million ≈ $2.20 Million	Skr227.60K ≈ $24.49K	0.011x	+100.76%
2017-12-31	Skr6.51 Million ≈ $700.81K	Skr-9.53 Million ≈ $-1.03 Million	-1.463x	+32.24%
2016-12-31	Skr4.08 Million ≈ $439.02K	Skr-8.81 Million ≈ $-947.94K	-2.159x	-252.65%
2015-12-31	Skr10.27 Million ≈ $1.10 Million	Skr-6.29 Million ≈ $-676.42K	-0.612x	-458.89%
2014-12-31	Skr5.67 Million ≈ $609.68K	Skr-620.67K ≈ $-66.79K	-0.110x	+75.90%
2013-12-31	Skr598.60K ≈ $64.42K	Skr-272.15K ≈ $-29.29K	-0.455x	-328.90%
2012-12-31	Skr298.09K ≈ $32.08K	Skr59.21K ≈ $6.37K	0.199x	--

About Novakand Pharma AB (publ)

ST:LARK USA Asset Management

Market Cap

$4.90 Million

Skr45.54 Million SEK

Market Cap Rank

#28666 Global

#5815 in USA

Share Price

Skr2.30

Change (1 day)

+0.00%

52-Week Range

Skr1.84 - Skr2.56

All Time High

Skr2.56